New Drug Approvals (Original) — May 11, 2026

ZHEJIANG NOVUS received FDA biosimilar approval for VORICONAZOLE (fallback type), signaling initial US commercialization potential for the sponsor despite neutral overall signal.

FDA approval of ZHEJIANG NOVUS's VORICONAZOLE biosimilar introduces competitive erosion risk for the originator, consistent with typical 30-60% revenue declines over 2-3 years for such events.

VORICONAZOLE originator faces revenue erosion from ZHEJIANG NOVUS biosimilar entry.

ZHEJIANG NOVUS gains US foothold with VORICONAZOLE biosimilar approval.

{"entity"=>"ZHEJIANG NOVUS", "reason"=>"VORICONAZOLE biosimilar approval signals potential US market entry", "trigger"=>"launch date, payer coverage decision"}

{"entity"=>"VORICONAZOLE originator", "reason"=>"New biosimilar approval from ZHEJIANG NOVUS introduces competition", "trigger"=>"ZHEJIANG NOVUS launch, initial sales erosion data"}